Berry Genomics, a Chinese genetic testing firm backed by Qiming Venture Partners and Legend Capital, is seeking to list in the A-share market via a reverse merger with Shenzhen-listed Chengdu Tianxing Instrument & Meter, according to a disclosure filing (in Chinese).
The Chengdu-based auto parts maker plan to acquire 100% of Berry Genomics through an asset exchange via issuing new shares to Berry Genomics, says the filing without disclosing any financial details of the proposed transaction.
Founded in 2010, Berry Genomics started with noninvasive prenatal DNA screening, and expanded to DNA sequencing and other forms of genetic testing for disease screening and diagnosis.
It received an undisclosed series A round...
This news article comes via , who is the copyright owner of this information and news. FintekAsia.com has licensed the rights to this article and any republication or re-distribution in whole or in part of this content is strictly prohibited without the express consent of China Money Network
